Results 301 to 310 of about 19,192,428 (324)

HDL-C: Role as a risk modifier

Atherosclerosis Supplements, 2011
Evidence that low-density lipoprotein-cholesterol (LDL-C) causes cardiovascular disease (CVD) is overwhelming. It has also been proven beyond all doubt that lowering the level of LDL-C using statins reduces CV risk. However, many people remain at high risk even when their level of LDL-C has been reduced by aggressive treatment with statins.
openaire   +2 more sources

Increasing HDL-C levels with medication: current perspectives

Current Opinion in Lipidology, 2017
Purpose of review To date, observational studies have repeatedly demonstrated an inverse association between HDL cholesterol (HDL-C) levels and cardiovascular outcomes. Although the efficacy of established HDL-modifying treatment strategies have been examined in multiple large-scale phase III trials, findings from these ...
Smit, R.A.J., Jukema, J.W., Trompet, S.
openaire   +3 more sources

New Drugs for HDL-C Disorders: The Beginning

Current Medicinal Chemistry, 2014
For more than 20 years there has been increasing interest in the development of novel therapies to raise levels of high-density lipoprotein cholesterol (HDL-C). However, well publicized failures of recent clinical trials of agents that raise HDL-C levels have stimulated considerable controversy with regard to the potential clinical utility of this ...
Duong, M., Nicholls, S.
openaire   +3 more sources

HDL-C: clinical equipoise and vascular endothelial function

Expert Review of Cardiovascular Therapy, 2013
Serum levels of HDL cholesterol represent a strong, and coherent cardiovascular risk marker seen across all populations, with higher levels of HDL cholesterol being associated with decreased incidence of coronary artery disease. The cardiovascular protective effects of HDL particles are attributed, in great part, to the ability of HDL particles to ...
Steven, Campbell, Jacques, Genest
openaire   +2 more sources

Effectiveness of simvastatin therapy in raising HDL-C in patients with type 2 diabetes and low HDL-C

Current Medical Research and Opinion, 2004
To evaluate the efficacy of high and moderate doses of simvastatin (80 and 40 mg), for raising high density lipoprotein-cholesterol (HDL-C), improving HDL sub-fractions, and affecting other parameters, including high sensitivity C-reactive protein (hs-CRP), in patients with type 2 diabetes mellitus (DM) and low HDL-C.This double-blind, placebo ...
Michael, Miller, Adrian, Dobs, Zhong, Yuan, Wendy P, Battisti, Hannah, Borisute, Joanne, Palmisano   +5 more
openaire   +2 more sources

Serum HDL-C levels, log (TG/HDL-C) values and serum total cholesterol/HDL-C ratios significantly correlate with radiological extent of disease in patients with community-acquired pneumonia

Clinical Biochemistry, 2006
In several studies, it was shown that there was a marked decrease in serum levels of HDL-C during infection and inflammation in general. In particular, a decrease in the level of serum HDL-C was also shown in pneumonia. Correlations between inflammatory markers such as acute phase proteins, cytokines and serum HDL-C levels were shown.
Omer, Deniz, Ergun, Tozkoparan, Halil, Yaman, Erdinc, Cakir, Seyfettin, Gumus, Omer, Ozcan, Ugur, Bozlar, Cumhur, Bilgi, Hayati, Bilgic, Kudret, Ekiz   +9 more
openaire   +2 more sources

Taking aim at HDL-C

Postgraduate Medicine, 2005
Although statin therapy has revolutionized management of coronary heart disease (CHD), the lowering of low-density lipoprotein cholesterol (LDL-C) levels is not the whole story. Increased plasma concentrations of high-density lipoprotein cholesterol (HDL-C) have a cardioprotective effect that is just as important for reducing risk of heart attack and ...
openaire   +2 more sources

Inverse correlation between homocysteine and HDL-C

Atherosclerosis, 2014
Project grants Science and Technology Foundation [PIC /IC/83020/2007] and Strategic Project Grant [PEst-OE/BIA/UI4046/2011].
A.R. Manaças, A.C. Alves, Q. Rato, M. Bourbon   +3 more
openaire   +1 more source

Different association of HDL-C, apoA-I, and HDL-C/apoA-I with multiple outcomes in HFrEF patients

International Journal of Cardiology
High-density lipoprotein-cholesterol (HDL-C) has been considered a cardioprotective factor for several decades. However, its association with outcomes in patients with heart failure with reduced ejection fraction (HFrEF) remains controversial. We aimed to investigate the association of HDL-C, apolipoprotein A-I (apoA-I), and the HDL-C/apoA-I ratio with
Ayiguli, Abudukeremu, Qiaofei, Chen, Zhanpeng, Pan, Xiao, Liu, Tongsheng, Huang, Yuan, Jiang, Hongwei, Li, Runlu, Sun, Hong, Pan, Kexin, Wen, Yue, Wang, Minglong, Zheng, Zizhuo, Su, Yuling, Zhang   +13 more
openaire   +2 more sources

Blocking endothelial lipase raises HDL-C levels

Nature Reviews Cardiology, 2021
openaire   +2 more sources